These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17204667)

  • 21. Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice.
    Tietge UJ; Maugeais C; Lund-Katz S; Grass D; deBeer FC; Rader DJ
    Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1213-8. PubMed ID: 12117740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased hepatic cholesterol accumulation in transgenic mice overexpressing human secretory phospholipase A2 group IIA.
    Eckey R; Menschikowski M; Lattke P; Jaross W
    Inflammation; 2004 Apr; 28(2):59-65. PubMed ID: 15379211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.
    Sato H; Kato R; Isogai Y; Saka G; Ohtsuki M; Taketomi Y; Yamamoto K; Tsutsumi K; Yamada J; Masuda S; Ishikawa Y; Ishii T; Kobayashi T; Ikeda K; Taguchi R; Hatakeyama S; Hara S; Kudo I; Itabe H; Murakami M
    J Biol Chem; 2008 Nov; 283(48):33483-97. PubMed ID: 18801741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function.
    Karabina SA; Brochériou I; Le Naour G; Agrapart M; Durand H; Gelb M; Lambeau G; Ninio E
    FASEB J; 2006 Dec; 20(14):2547-9. PubMed ID: 17077289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice.
    Fraser H; Hislop C; Christie RM; Rick HL; Reidy CA; Chouinard ML; Eacho PI; Gould KE; Trias J
    J Cardiovasc Pharmacol; 2009 Jan; 53(1):60-5. PubMed ID: 19129734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100.
    Flood C; Gustafsson M; Pitas RE; Arnaboldi L; Walzem RL; Borén J
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):564-70. PubMed ID: 14726411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autocrine and paracrine transcriptional regulation of type IIA secretory phospholipase A2 gene in vascular smooth muscle cells.
    Jaulmes A; Janvier B; Andreani M; Raymondjean M
    Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1161-7. PubMed ID: 15802623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
    Luchtefeld M; Bandlow N; Tietge UJ; Grote K; Pfeilschifter J; Kaszkin M; Beck S; Drexler H; Schieffer B
    Atherosclerosis; 2007 Sep; 194(1):62-70. PubMed ID: 17069818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction.
    Ohtsuki M; Taketomi Y; Arata S; Masuda S; Ishikawa Y; Ishii T; Takanezawa Y; Aoki J; Arai H; Yamamoto K; Kudo I; Murakami M
    J Biol Chem; 2006 Nov; 281(47):36420-33. PubMed ID: 17008322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study.
    Wootton PT; Arora NL; Drenos F; Thompson SR; Cooper JA; Stephens JW; Hurel SJ; Hurt-Camejo E; Wiklund O; Humphries SE; Talmud PJ
    Hum Mol Genet; 2007 Jun; 16(12):1437-44. PubMed ID: 17545304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydrolysis of lipoproteins by sPLA2's enhances mitogenesis and eicosanoid release from vascular smooth muscle cells: Diverse activity of sPLA2's IIA, V and X.
    Pruzanski W; Kopilov J; Kuksis A
    Prostaglandins Other Lipid Mediat; 2016 Jan; 122():64-8. PubMed ID: 26711221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?
    Menschikowski M; Hagelgans A; Siegert G
    Prostaglandins Other Lipid Mediat; 2006 Mar; 79(1-2):1-33. PubMed ID: 16516807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydrolysis of minor glycerophospholipids of plasma lipoproteins by human group IIA, V and X secretory phospholipases A2.
    Pruzanski W; Lambeau G; Lazdunski M; Cho W; Kopilov J; Kuksis A
    Biochim Biophys Acta; 2007 Jan; 1771(1):5-19. PubMed ID: 17197234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Group V secretory phospholipase A2 translocates to the phagosome after zymosan stimulation of mouse peritoneal macrophages and regulates phagocytosis.
    Balestrieri B; Hsu VW; Gilbert H; Leslie CC; Han WK; Bonventre JV; Arm JP
    J Biol Chem; 2006 Mar; 281(10):6691-8. PubMed ID: 16407308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telmisartan and N-acetylcysteine suppress group V secretory phospholipase A2 expression in TNFα-stimulated human endothelial cells and reduce associated atherogenicity.
    Sonoki K; Iwase M; Ohdo S; Ieiri I; Matsuyama N; Takata Y; Kitazono T
    J Cardiovasc Pharmacol; 2012 Oct; 60(4):367-74. PubMed ID: 22743636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL.
    Pruzanski W; Stefanski E; de Beer FC; de Beer MC; Vadas P; Ravandi A; Kuksis A
    J Lipid Res; 1998 Nov; 39(11):2150-60. PubMed ID: 9799801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute inflammation increases selective uptake of HDL cholesteryl esters into adrenals of mice overexpressing human sPLA2.
    Tietge UJ; Maugeais C; Cain W; Rader DJ
    Am J Physiol Endocrinol Metab; 2003 Aug; 285(2):E403-11. PubMed ID: 12637261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice.
    Zhang WJ; Bird KE; McMillen TS; LeBoeuf RC; Hagen TM; Frei B
    Circulation; 2008 Jan; 117(3):421-8. PubMed ID: 18158360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. P55 tumour necrosis factor receptor in bone marrow-derived cells promotes atherosclerosis development in low-density lipoprotein receptor knock-out mice.
    Xanthoulea S; Gijbels MJ; van der Made I; Mujcic H; Thelen M; Vergouwe MN; Ambagts MH; Hofker MH; de Winther MP
    Cardiovasc Res; 2008 Nov; 80(2):309-18. PubMed ID: 18628255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
    Rahtu-Korpela L; Määttä J; Dimova EY; Hörkkö S; Gylling H; Walkinshaw G; Hakkola J; Kivirikko KI; Myllyharju J; Serpi R; Koivunen P
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):608-17. PubMed ID: 26848160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.